Pivotal Point Tracking Guardant Health (GH): Shield Blood Test Breakthrough - Mega Deal with U.S. Insurer UnitedHealth

Guardant Health is a leading precision oncology company specializing in liquid biopsies for cancer detection. Its main sources of revenue are advanced cancer tests for clinical and biopharma research. In Q1, revenue rose by 48% to $301.7 million, with the screening segment increasing by over 600% to $41.6 million. Due to this momentum, management raised its 2026 annual forecast to $1.30 to $1.32 billion. On July 1, the news that UnitedHealth Group would cover the "Shield" blood test for colorectal cancer screening caused the stock to surge. The...